Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the treatment of Type 2 diabetes in adults.Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza). Xultophy is indicated for the treatment of adults with Type 2 diabetes mellitus to improve glycemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycemic control.
The authorization covers all 27 European Union member states. Xultophy was approved in Switzerland on 12 September 2014. Novo Nordisk expects to launch Xultophy in the first European countries in the first half of 2015.
